This section covers all aspects of preclinical investigations on therapeutic agents. It welcomes submissions concerning anti-cancer drug discovery and development, and targeted therapies.
Development of an engineered peptide antagonist against periostin to overcome doxorubicin resistance in breast cancer
Chemoresistance is one of the main problems in treatment of cancer. Periostin (PN) is a stromal protein which is mostly secreted from cancer associated fibroblasts in the tumor microenvironment and can promote...
Citation: BMC Cancer 2021 21:65